Anticancer  ||| S:0 E:11 ||| JJ
effect  ||| S:11 E:18 ||| NN
of  ||| S:18 E:21 ||| IN
xanthohumol  ||| S:21 E:33 ||| JJ
induces  ||| S:33 E:41 ||| JJ
growth  ||| S:41 E:48 ||| NN
inhibition  ||| S:48 E:59 ||| NNS
and  ||| S:59 E:63 ||| CC
apoptosis  ||| S:63 E:73 ||| NN
of  ||| S:73 E:76 ||| IN
human  ||| S:76 E:82 ||| JJ
liver  ||| S:82 E:88 ||| NN
cancer  ||| S:88 E:95 ||| NN
through  ||| S:95 E:103 ||| IN
NF-κB ||| S:103 E:108 ||| FW
/ ||| S:108 E:109 ||| FW
p53-apoptosis  ||| S:109 E:123 ||| FW
signaling  ||| S:123 E:133 ||| FW
pathway  ||| S:133 E:141 ||| FW
Xanthohumol  ||| S:141 E:153 ||| NNP
may  ||| S:153 E:157 ||| MD
prevent  ||| S:157 E:165 ||| VB
and  ||| S:165 E:169 ||| CC
cure  ||| S:169 E:174 ||| JJ
diabetes  ||| S:174 E:183 ||| NN
and  ||| S:183 E:187 ||| CC
atherosis ||| S:187 E:196 ||| NN
,  ||| S:196 E:198 ||| ,
have  ||| S:198 E:203 ||| VBP
oxidation  ||| S:203 E:213 ||| JJ
resistance  ||| S:213 E:224 ||| NN
and  ||| S:224 E:228 ||| CC
antiviral  ||| S:228 E:238 ||| JJ
function  ||| S:238 E:247 ||| NN
as  ||| S:247 E:250 ||| IN
well  ||| S:250 E:255 ||| RB
as  ||| S:255 E:258 ||| IN
anticancer  ||| S:258 E:269 ||| JJ
effect  ||| S:269 E:276 ||| NN
preventing  ||| S:276 E:287 ||| VBG
cancer  ||| S:287 E:294 ||| NN
cell  ||| S:294 E:299 ||| NN
metastasis ||| S:299 E:309 ||| NN
.  ||| S:309 E:311 ||| .
We  ||| S:311 E:314 ||| PRP
investigate  ||| S:314 E:326 ||| VB
whether  ||| S:326 E:334 ||| IN
the  ||| S:334 E:338 ||| DT
anticancer  ||| S:338 E:349 ||| JJ
effect  ||| S:349 E:356 ||| NN
of  ||| S:356 E:359 ||| IN
xanthohumol  ||| S:359 E:371 ||| JJ
induces  ||| S:371 E:379 ||| JJ
growth  ||| S:379 E:386 ||| NN
inhibition  ||| S:386 E:397 ||| NNS
and  ||| S:397 E:401 ||| CC
apoptosis  ||| S:401 E:411 ||| NN
of  ||| S:411 E:414 ||| IN
human  ||| S:414 E:420 ||| JJ
liver  ||| S:420 E:426 ||| NN
cancer  ||| S:426 E:433 ||| NN
through  ||| S:433 E:441 ||| IN
NF-κB ||| S:441 E:446 ||| FW
/ ||| S:446 E:447 ||| FW
p53-apoptosis  ||| S:447 E:461 ||| FW
signaling  ||| S:461 E:471 ||| FW
pathway ||| S:471 E:478 ||| FW
.  ||| S:478 E:480 ||| .
Human  ||| S:480 E:486 ||| JJ
liver  ||| S:486 E:492 ||| NN
cancer  ||| S:492 E:499 ||| NN
HepG2  ||| S:499 E:505 ||| CD
cell  ||| S:505 E:510 ||| NN
were  ||| S:510 E:515 ||| VBD
treated  ||| S:515 E:523 ||| VBN
with  ||| S:523 E:528 ||| IN
10 ||| S:528 E:530 ||| CD
,  ||| S:530 E:532 ||| ,
20 ||| S:532 E:534 ||| CD
,  ||| S:534 E:536 ||| ,
30  ||| S:536 E:539 ||| CD
and  ||| S:539 E:543 ||| CC
40 µM  ||| S:543 E:549 ||| CD
xanthohumol  ||| S:549 E:561 ||| NN
for  ||| S:561 E:565 ||| IN
48 h ||| S:565 E:569 ||| CD
.  ||| S:569 E:571 ||| .
The  ||| S:571 E:575 ||| DT
present  ||| S:575 E:583 ||| JJ
study  ||| S:583 E:589 ||| NN
showed  ||| S:589 E:596 ||| VBD
that  ||| S:596 E:601 ||| IN
the  ||| S:601 E:605 ||| DT
anticancer  ||| S:605 E:616 ||| JJ
effect  ||| S:616 E:623 ||| NN
of  ||| S:623 E:626 ||| IN
xanthohumol  ||| S:626 E:638 ||| NN
was  ||| S:638 E:642 ||| VBD
effective  ||| S:642 E:652 ||| JJ
in  ||| S:652 E:655 ||| IN
inhibiting  ||| S:655 E:666 ||| JJ
proliferation  ||| S:666 E:680 ||| NN
and  ||| S:680 E:684 ||| CC
inducing  ||| S:684 E:693 ||| JJ
apoptosis  ||| S:693 E:703 ||| NN
of  ||| S:703 E:706 ||| IN
human  ||| S:706 E:712 ||| JJ
liver  ||| S:712 E:718 ||| NN
cancer  ||| S:718 E:725 ||| NN
HepG2  ||| S:725 E:731 ||| CD
cells ||| S:731 E:736 ||| NNS
.  ||| S:736 E:738 ||| .
Furthermore ||| S:738 E:749 ||| RB
,  ||| S:749 E:751 ||| ,
the  ||| S:751 E:755 ||| DT
caspase-3  ||| S:755 E:765 ||| JJ
activity  ||| S:765 E:774 ||| NN
of  ||| S:774 E:777 ||| IN
human  ||| S:777 E:783 ||| JJ
liver  ||| S:783 E:789 ||| NN
cancer  ||| S:789 E:796 ||| NN
HepG2  ||| S:796 E:802 ||| CD
cells  ||| S:802 E:808 ||| NNS
was  ||| S:808 E:812 ||| VBD
increased  ||| S:812 E:822 ||| VBN
by  ||| S:822 E:825 ||| IN
xanthohumol ||| S:825 E:836 ||| NN
.  ||| S:836 E:838 ||| .
In  ||| S:838 E:841 ||| IN
addition ||| S:841 E:849 ||| NN
,  ||| S:849 E:851 ||| ,
48-h  ||| S:851 E:856 ||| CD
treatment  ||| S:856 E:866 ||| NN
with  ||| S:866 E:871 ||| IN
xanthohumol  ||| S:871 E:883 ||| JJ
suppressed  ||| S:883 E:894 ||| JJ
NF-κB  ||| S:894 E:900 ||| JJ
expression  ||| S:900 E:911 ||| NN
and  ||| S:911 E:915 ||| CC
promoted  ||| S:915 E:924 ||| JJ
p53 ||| S:924 E:927 ||| NN
,  ||| S:927 E:929 ||| ,
cleaved  ||| S:929 E:937 ||| VBG
PARP ||| S:937 E:941 ||| NNP
,  ||| S:941 E:943 ||| ,
AIF  ||| S:943 E:947 ||| NNP
and  ||| S:947 E:951 ||| CC
cytochrome c  ||| S:951 E:964 ||| CD
expression  ||| S:964 E:975 ||| NN
and  ||| S:975 E:979 ||| CC
downregulated  ||| S:979 E:993 ||| JJ
XIAP  ||| S:993 E:998 ||| NNP
and  ||| S:998 E:1002 ||| CC
Bcl-2 ||| S:1002 E:1007 ||| NNP
/ ||| S:1007 E:1008 ||| NNP
Bax  ||| S:1008 E:1012 ||| NNP
expression  ||| S:1012 E:1023 ||| NN
in  ||| S:1023 E:1026 ||| IN
human  ||| S:1026 E:1032 ||| JJ
liver  ||| S:1032 E:1038 ||| NN
cancer  ||| S:1038 E:1045 ||| NN
HepG2  ||| S:1045 E:1051 ||| CD
cells ||| S:1051 E:1056 ||| NNS
.  ||| S:1056 E:1058 ||| .
Therefore ||| S:1058 E:1067 ||| RB
,  ||| S:1067 E:1069 ||| ,
the  ||| S:1069 E:1073 ||| DT
anticancer  ||| S:1073 E:1084 ||| JJ
effect  ||| S:1084 E:1091 ||| NN
of  ||| S:1091 E:1094 ||| IN
xanthohumol  ||| S:1094 E:1106 ||| JJ
induces  ||| S:1106 E:1114 ||| JJ
growth  ||| S:1114 E:1121 ||| NN
inhibition  ||| S:1121 E:1132 ||| NNS
and  ||| S:1132 E:1136 ||| CC
apoptosis  ||| S:1136 E:1146 ||| NN
of  ||| S:1146 E:1149 ||| IN
human  ||| S:1149 E:1155 ||| JJ
liver  ||| S:1155 E:1161 ||| NN
cancer  ||| S:1161 E:1168 ||| NN
through  ||| S:1168 E:1176 ||| IN
the  ||| S:1176 E:1180 ||| DT
NF-κB ||| S:1180 E:1185 ||| JJ
/ ||| S:1185 E:1186 ||| FW
p53-apoptosis  ||| S:1186 E:1200 ||| FW
signaling  ||| S:1200 E:1210 ||| FW
pathway ||| S:1210 E:1217 ||| FW
.  ||| S:1217 E:1219 ||| .
